PCN24 Budget IMPACT Analysis (BIA) of Introducing Tisagenlecleucel for the Treatment of Patients with Relapsed and Refractory Diffuse Large B-CELL Lymphoma (R/R DLBCL) in Singapore (SG)
Abstract
Authors
J. Wang X. Wang S. Lakhanpal A. Latour